This study focuses on patients with neovascular Age-Related Macular Degeneration, also known as wet AMD, which is an eye condition causing vision loss due to abnormal blood vessel growth in the retina. The study tests a device called the Port Delivery System that contains the medicine ranibizumab. This system is designed to deliver medication directly into the eye through a small, implantable device, rather than through traditional eye injections.
The purpose of this research is to evaluate how well the Port Delivery System works when the medicine is refilled every 36 weeks. The medication being studied, ranibizumab, is already approved for treating wet AMD when given as regular eye injections. In this study, participants will receive the implanted delivery system and will have it refilled with medication according to a set schedule over approximately 72 weeks.
During the study, patients will have regular eye examinations and vision tests to monitor their condition. The Port Delivery System will be surgically implanted into the eye at the beginning of the study, and then the medicine will be refilled through this system. The study will compare this new delivery method to traditional eye injections and will monitor both the effectiveness of the treatment and any side effects that may occur.
Austria 
Czechia 
Denmark 
France 
Germany 
Greece 
Italy 
Poland 
Spain 
